¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor host interaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® host ÇÑ±Û ¼÷ÁÖ
¼³¸í   
  ´Ù¸¥ »ý¹°(±â»ýü)À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇϴ µ¿¹° ¶Ç´Â ½Ä¹°. ¸¶Áö¸·ÀÇ ¼öÁÖ¸¦ Á¾¼÷ÁÖ, ¹ßÀ°ÀÇ µµÁß¿¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£ ¼÷ÁÖ¶ó°í ÇÑ´Ù. ±â»ýµ¿¹° Áß¿¡´Â ¼÷ÁÖ°¡ Æ¯Á¤ÇÑ Á¾ÀÏ ¶§µµ ÀÖ°í ¶Ç ¸¹Àº ±â»ýÃæ°ú °°À̱נ¹ß»ý´Ü°è¿¡ µû¶ó ¸¹Àº Á¾·ùÀÇ ¼÷ÁÖ¸¦ ÇÊ¿ä·Î Çϴ °Íµµ ÀÖ´Ù. ÀÌ °æ¿ì ¾Ö¹ú·¹°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£¼÷ÁÖ, ¼ºÃ¼°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ ÃÖÁ¾¼÷ÁÖ¶ó°í ÇÑ´Ù. °£ÁúÀΠ°æ¿ì¿¡´Â ¹°°íµ¿ÀÌ Áß°£¼÷ÁÖÀ̰í, ¼Ò-¾ç µîÀº ÃÖÁ¾¼÷ÁÖ°¡ µÈ´Ù. ±â»ý½Ä¹°¿¡´Â °Ü¿ì»ìÀ̿͠°°ÀÌ Á¹Âü³ª¹« µîÀ» ¼÷ÁַΠÇÏ¿© ½º½º·Î ±¤ÇÕ¼ºÀ» Çϸ鼭µµ ¼÷ÁÖ¿¡°Ô¼­ ¿µ¾çÀ» ¾ò´Â °Í°ú, ¾ß°í¿Í °°ÀÌ »ý°­ µîÀÇ »Ñ¸®¸¦ ¼÷ÁַΠÇÏ¿© ¼÷ÁÖ¿¡°Ô¼­¸¸ ¿µ¾çÀ» ÀÇÁ¸Çϴ °ÍÀÌ ÀÖ´Ù. ±â»ý»ý¹°¿¡´Â ÀÌ ¹Û¿¡µµ »ý¹°ÀÇ »çü³ª ±× ºÐÇØÁß¿¡ Àִ °Í, ¹èÃâ¹° µîÀ» ¼÷ÁַΠÇϴ °Íµµ ÀÖ´Ù.
¿µ¹® graft versus host reaction ÇÑ±Û ÀÌ½ÄÆí´ë ¼÷ÁÖ¹ÝÀÀ
¼³¸í   
  ¸é¿ªÀ̶õ ÀÚ½ÅÀÇ °Í°ú ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» ±¸ºÐÇØ¼­ ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» °ø°ÝÇÏ¿© »ý¹°ÇÐÀû È°¼ºÀ» ¾ø¾Ö°Å³ª Á¦°ÅÇϴ °ÍÀÌ´Ù. ÀÌ ¸é¿ªÀº ÁַΠÇ÷¾×¿¡ Àִ ¼¼Æ÷¿¡ ÀÇÇØ¼­ ÀÌ·ç¾îÁø´Ù. Æ¯È÷ ¸²ÇÁ±¸´Â ÀÌ ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù. ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀÀ̶ó´Â °ÍÀº À̽ĵǾî¿Â Á¶Á÷¿¡ Á¸ÀçÇϴ ŸÀÎÀÇ Ç÷±¸µéÀÌ ¼÷ÁÖÀÇ ¼¼Æ÷¸¦ °ø°ÝÇϴ °ÍÀ» ¸»ÇÑ´Ù. Áï À̽ĵǾî¿Â Á¶Á÷°ú ÇÔ²² µé¾î¿Â Ç÷±¸µéÀÌ À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¼¼Æ÷¸¦ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÇϴ Çö»óÀÌ´Ù. À̰ÍÀº À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¸é¿ª»óŰ¡ Á¤»óÀûÀÏ °æ¿ì¿¡´Â ÀϾÁö ¾Ê´Âµ¥ ¿Ö³ÄÇϸ頸鿪»óŰ¡ Á¤»óÀÏ °æ¿ì¿¡´Â À̽ĵǾî¿Â Àå±â¿Í ´õºÒ¾î µé¾î¿Â Å¸ÀÎÀÇ Ç÷±¸µéÀ» À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ Ç÷±¸°¡ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÀ» ÇÏ°í ¼ýÀûÀ¸·Î À¯¸®ÇÏ¿© ¸ðµÎ Á×ÀÏ ¼ö°¡ Àֱ⠶§¹®ÀÌ´Ù.
¿µ¹® solid tumor ÇÑ±Û °íÇüÁ¾¾ç
¼³¸í   
  ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀΠ»óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼­ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. Æ¯È÷ Ç¥ÇÇÁ¶Á÷¿¡¼­ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù.
¿µ¹® ulcerating tumor ÇÑ±Û ±Ë¾ç¼º Á¾¾ç
¼³¸í   
  Á¾¾çÀǠǥ¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇϴ °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼­ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇϴ °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿­À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ.
¿µ¹® brain tumor ÇÑ±Û ³úÁ¾¾ç
¼³¸í   
  ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼­ »ý±ä Á¾¾çÀ» ÁöĪÇϴ ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀΠµÎ°³°­¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù.
  
  ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀΠµÎ°³°­¿¡¼­ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀΠÁ¶Á÷À» ¾Ð¹ÚÇϰԠµÇ°í, µÎ°³°­³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Æ¯Â¡¿¡ ÀÇÇØ¼­ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀΠ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼­ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀΠ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇϴ ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • additive interaction
    »ó°¡ÀÛ¿ë
  • binocular interaction
    µÎ´«»óÈ£ÀÛ¿ë, ¾ç¾È»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯Àü»óÈ£ÀÛ¿ë
  • infant-mother interaction
    ¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë
  • orbit interaction
    ±Ëµµ»óÈ£ÀÛ¿ë
  • primary interaction
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • radiation interaction
    ¹æ»ç¼±»óÈ£ÀÛ¿ë
  • simple interaction
    ´Ü¼ø»óÈ£ÀÛ¿ë
  • accidental host
    ¿ì¿¬¼÷ÁÖ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interaction
    »óÈ£ÀÛ¿ë
  • sex cord-stromal tumor tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host
    ¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • tumor antigen
    Á¾¾çÇ׿ø
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • tumor marker
    Á¾¾çÇ¥ÁöÀÚ
  • tumor size
    Á¾¾çÅ©±â
  • tumor
    Á¾¾ç
  • adenomatoid tumor
    »ù¸ð¾çÁ¾¾ç, »ùÁ¾´àÀºÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • additive interaction
    »ó°¡ÀÛ¿ë
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • binocular interaction
    ¾ç¾È»óÈ£ÀÛ¿ë, µÎ´«»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯Àü»óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë
  • infant-mother interaction
    ¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
  • orbit interaction
    ±Ëµµ»óÈ£ÀÛ¿ë
  • primary interaction
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • radiation interaction
    ¹æ»ç¼±»óÈ£ÀÛ¿ë
  • receptor-ligand interaction
    ¼ö¿ëü¹èÀ§ÀÚ»óÈ£ÀÛ¿ë
  • simple interaction
    ´Ü¼ø»óÈ£ÀÛ¿ë
  • tissue interaction
    Á¶Á÷»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ.
  • pneumonia,in immunocompromised host
    ¸é¿ª±â´ÉÀúÇϼ÷ÁÖÀÇ (Øóæ¹Ñ¦Òöî¸ù»âÖñ«¡­)
  • relation[ship], host-parasite
    ¼÷ÁÖ-±â»ýü »óÈ£°ü°è
  • J-coupling interaction
    J °áÇÕ »óÈ£ÀÛ¿ë
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • additive interaction
    »ó°¡(ßÓÊ¥)ÀÛ¿ë.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor host interaction
    Á¾¾ç¼÷ÁÖ»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • compromised host
    ÀúÇ×·Â ÀúÇϼ÷ÁÖ
  • definitive host =final h.
    ÃÖÁ¾¼÷ÁÖ(¡­âÖñ«).
  • final host
    ÃÖÁ¾¼÷ÁÖ, Á¾¼÷ÁÖ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ.
  • host attribute
    ¼÷ÁÖ¼Ó¼º.
  • host computer
    ÁÖ ÄÄÇ»ÅÍ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Host
    ¼÷ÁÖ
    [¿¾ ¿ë¾î] ¼÷ÁÖ
  • Deficiency (Monstrous tumor)
    °áÇÌ (±«¹°Á¾)
    [¿¾ ¿ë¾î] °áÇÌ
  • Monstrous tumor
    ±«¹°Á¾
    [¿¾ ¿ë¾î] ±«¹°Á¾
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • alternate host
    ±³´ë¼÷ÁÖ
  • amplifier host
    ÁõÆø¼÷ÁÖ
  • crustacean host
    °©°¢·ù¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • first intermediate host
    Á¦ÀÏÁß°£¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host parasite relationship
    ¼÷ÁÖ±â»ýÃæ°ü°è
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • host-parasite specificity
    ¼÷ÁÖ±â»ýÃæÆ¯À̼º
  • intermediate host
    Áß°£¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cloning host
    Ŭ·Î´× ¼÷ÁÖ(âÖñ«)
  • host
    ¼÷ÁÖ(âÖñ«)
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
  • host-controlled modification
    ¼÷ÁÖÁ¦¾î ¼ö½Ä(âÖñ«ð¤åÙáóãÞ)
  • host-controlled restriction
    ¼÷ÁÖÁ¦¾î Á¦ÇÑ(âÖñ«ð¤åÙð¤ùÚ)
  • host-guest system
    ÁÖ-°´(ñ«-ËÔ) ½Ã½ºÅÛ
  • host-induced modification
    ¼÷ÁÖÀ¯µµ ¼ö½Ä(âÖñ«ë¯ÓôáóãÞ)
  • host range
    ¼÷ÁÖ ¹üÀ§(âÖñ«ÛôêÌ)
  • host-range mutant
    ¼÷ÁÖ¹üÀ§ º¯ÀÌÁÖ(âÖñ«ÛôêÌܨì¶ñ»)
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • ectopic tumor
    ÀÌ¼Ò Á¾¾ç(ì¶á¶ðþåË)
  • Ehrlich ascites tumor
    ¿¡¸¦¸®È÷ º¹¼öÁ¾(ÜÙâ©ðþ)
  • primary tumor
    ¿ø¹ß¼º Á¾¾ç(ê«Û¡àõðþåË)
  • tumor angiogenesis facotr
    Á¾¾ç Ç÷°üÇü¼ºÀÎÀÚ(ðþåËúìηû¡à÷ì×í­)
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host
    ¼÷ÁÖ, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
  • host computer
    ÁÖÄÄÇ»ÅÍ
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • dipole dipole interaction
    ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • intermolecular dipole dipole interaction
    ºÐÀÚ°£½Ö±ØÀÚ°£»óÈ£ÀÛ¿ë
  • intramolecular dipole dipole interaction
    ºÐÀÚ³»½Ö±ØÀÚ°£»óÈ£ÀÛ¿ë
  • J-coupling interaction
    J°áÇÕ»óÈ£ÀÛ¿ë
  • proton electron dipole dipole interaction
    ¾çÀÚÀüÀÚ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£¹ÝÀÀ
  • proton proton dipole dipole interaction
    ¾çÀÚ¾çÀÚ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£¹ÝÀÀ
  • tissue interaction
    Á¶Á÷°£ÀÇ »óÈ£ÀÛ¿ë
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • brown tumor
    °¥»öÁ¾¾ç
  • carotid body tumor
    °æµ¿¸Æ¼ÒüÁ¾¾ç
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
  • glomus jugulare tumor
    °æÁ¤¸Æ±¸Á¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
BT base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
TNM primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas...
ISSI interview schedule for social interaction; Israeli Study of Surgical Infections
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TBH Tumor-bearing host
BI Binaural Interaction
BIA Biomolecular Interaction Analysis
BIA Biospecific Interaction Analysis
HCI Human Computer Interaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • host
    ¼÷ÁÖ, °³Ã¼, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
    1. ¼÷ÁÖ-´Ù¸¥ »ý¹°À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇÏ´Â µ¿¹° ¶Ç´Â ½Ä¹°. 2. ÇÇÀ̽Äü, ¼ö¿ëÀÚ-´Ù¸¥ »ý¹°·ÎºÎÅÍ ±â°ü ¶Ç´Â Á¶Á÷ÀÇ À̽ÄÀ» ¹Þ´Â ¼ö¿ëÀÚ.
  • host-parasitite relationship
    ¼÷ÁÖ-±â»ýüÀÇ »óÈ£ °ü°è
  • pneumonia,in immunocompromised host
    ¸é¿ª ±â´É ÀúÇÏ ¼÷ÁÖÀÇ
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • additive interaction
    »ó°¡ ÀÛ¿ë
  • heme heme interaction
    Èû-Èû »óÈ£ÀÛ¿ë
  • high-power interaction
    °íÃâ·Â »óÈ£ ÀÛ¿ë
  • interaction
    »óÈ£ ÀÛ¿ë
    µÎ °³ ¶Ç´Â ±× ÀÌ»óÀÌ ¼­·Î ¼­·Î ÀÛ¿ëÇÏ´Â ¼ºÁú, »óųª °úÁ¤.
  • nonthermal interaction
    ºñ¿­ »óÈ£ÀÛ¿ë
  • photochemical interaction
    ±¤È­ÇÐ ¹ÝÀÀ
  • photothermal interaction
    ±¤¿­ ¹ÝÀÀ
  • proton proton dipole dipole interaction
    ¾çÀÚ ¾çÀÚ ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ ¹ÝÀÀ
  • triple interaction
    »ïÁß »óÈ£ ÀÛ¿ë
  • acoustic tumor
    û½Å°æ Á¾¾ç
    Á¦ 8 ½Å°æ¿¡¼­ »ý±ä ¾ç¼º Á¾¾ç.
  • ACTH-secreting tumor
    ACTH-ºÐºñ Á¾¾ç
    µ¿ÀǾî=corticotro
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
tumor 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant.
2. Swelling, one of the cardinal signs of inflammations, morbid enlargement.
Origin: L. Tumere = to swell
(12 May 1997)
tumor marker <investigation, oncology> A substance in the body that usually indicates the presence of cancer.
These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples.
Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH).
They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
(18 Jul 2002)
tumor necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
apolar interaction <chemistry> The attractive force between molecules due to the close positioning of non-hydrophilic portions of the two molecules.
(09 Oct 1997)
hydrophobic interaction <chemistry> The attractive force between molecules due to the close positioning of non-hydrophilic portions of the two molecules.
(09 Oct 1997)
specimen interaction <microscopy> Reactions that occur inside the specimen when being struck with a beam of energetic electrons or ions.
(05 Aug 1998)
specimen interaction volume <microscopy> The volume inside the specimen in which all specimen interactions occur during electron beam irradiation.
(05 Aug 1998)
DNA-protein interaction <molecular biology> Any complex that forms between a protein molecule and DNA.
Examples are nucleosomes (structures formed for the purpose of DNA storage) and any gene regulatory protein (a protein which regulates transcription by binding to a regulatory region on the DNA).
(09 Oct 1997)
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
interaction The quality, state or process of (two or more things) acting on each other.
(18 Nov 1997)
interaction process analysis In psychology, analysis of small group behaviour in terms of 12 specific categories, e.g., solidarity, tension release, agreement.
(05 Mar 2000)
accidental host One that harbors an organism which usually does not infect it.
(05 Mar 2000)
amplifier host A host in which infectious agents multiply rapidly to high levels, providing an important source of infection for vectors in vector-borne diseases.
(05 Mar 2000)
parasite-host ecosystem Complex of all parasite species and individuals associated with a specific host.
Synonym: parasite-host ecosystem.
Origin: parasite + G. Koinos, common, together
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor
    Á¾±â
  • tumor
    Á¾Ã¢;ºÎ±â;Á¾±â
  • interaction
    »óÈ£ÀÛ¿ë
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë;»óÈ£ÀÇ ¿µÇâ
  • a host of
    -ÀÌ ¸¹Àº
  • host
    ÁÖÀÎ; ±ºÁß; ¹«¸®
  • definitive host
    (»ý)Á¾°á(°íÀ¯)¼÷ÁÖ
  • host
    (¼Õ´Ô¿¡ ´ëÇÏ¿©) ÁÖÀÎ;(¿©°üÀÇ) (³²ÀÚ) ÁÖÀÎ;(±â»ý »ý¹°ÀÇ) ¼÷ÁÖ;reckon(count) without one's ~ Á¦¸Ú´ë·Î Ä¡ºÎ(ÆÇ´Ü)ÇÏ´Ù
  • host
    ¸¹Àº ¶¼;´Ù¼ö;±º¼¼;heavenly ~s;~(s) of heaven ÇÏ´ÃÀÇ º°;õ»çÀÇ ¶¼
  • host city
    (°æ±â µîÀÇ)°³ÃÖ µµ½Ã
  • host computer
    (´Ü¸»±â,¸¶ÀÌÅ©·Î ÄÄÇ»Å͸¦ °Å´À¸°)È£½ºÆ® ÄÄÇ»ÅÍ;´ë¿ë·® ÄÄÇ»ÅÍ
  • host plant
    ±âÁÖ ½Ä¹°
  • intermediate host
    Áß°£¼÷ÁÖ(±â»ýÃæÀÇ À¯»ý±âÀÇ ¼÷ÁÖ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á